Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, do...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/1/185 |
| _version_ | 1797710805311946752 |
|---|---|
| author | Nicoletta Coccaro Luisa Anelli Antonella Zagaria Tommasina Perrone Giorgina Specchia Francesco Albano |
| author_facet | Nicoletta Coccaro Luisa Anelli Antonella Zagaria Tommasina Perrone Giorgina Specchia Francesco Albano |
| author_sort | Nicoletta Coccaro |
| collection | DOAJ |
| description | Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone—R-CHOP), which allows a 60% overall survival (OS) rate, but up to 40% of patients experience relapse or refractory (R/R) disease. With the purpose of searching for new clinical parameters and biomarkers helping to make a better DLBCL patient characterization and stratification, in the last years a series of large discovery genomic and transcriptomic studies has been conducted, generating a wealth of information that needs to be put in order. We reviewed these researches, trying ultimately to understand if there are bases offering a roadmap toward personalized and precision medicine also for DLBCL. |
| first_indexed | 2024-03-12T06:57:35Z |
| format | Article |
| id | doaj.art-ee5be03b3fb24342a8fa49efbce95dbf |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:57:35Z |
| publishDate | 2020-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ee5be03b3fb24342a8fa49efbce95dbf2023-09-02T23:59:33ZengMDPI AGCancers2072-66942020-01-0112118510.3390/cancers12010185cancers12010185Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?Nicoletta Coccaro0Luisa Anelli1Antonella Zagaria2Tommasina Perrone3Giorgina Specchia4Francesco Albano5Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, ItalyDepartment of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, ItalyDepartment of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, ItalyDepartment of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, ItalyDepartment of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, ItalyDepartment of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, 70124 Bari, ItalyDiffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone—R-CHOP), which allows a 60% overall survival (OS) rate, but up to 40% of patients experience relapse or refractory (R/R) disease. With the purpose of searching for new clinical parameters and biomarkers helping to make a better DLBCL patient characterization and stratification, in the last years a series of large discovery genomic and transcriptomic studies has been conducted, generating a wealth of information that needs to be put in order. We reviewed these researches, trying ultimately to understand if there are bases offering a roadmap toward personalized and precision medicine also for DLBCL.https://www.mdpi.com/2072-6694/12/1/185diffuse large b-cell lymphoma (dlbcl)coo classificationnext-generation sequencing (ngs)biomarkerliquid biopsytargeted therapy |
| spellingShingle | Nicoletta Coccaro Luisa Anelli Antonella Zagaria Tommasina Perrone Giorgina Specchia Francesco Albano Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? Cancers diffuse large b-cell lymphoma (dlbcl) coo classification next-generation sequencing (ngs) biomarker liquid biopsy targeted therapy |
| title | Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? |
| title_full | Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? |
| title_fullStr | Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? |
| title_full_unstemmed | Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? |
| title_short | Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? |
| title_sort | molecular complexity of diffuse large b cell lymphoma can it be a roadmap for precision medicine |
| topic | diffuse large b-cell lymphoma (dlbcl) coo classification next-generation sequencing (ngs) biomarker liquid biopsy targeted therapy |
| url | https://www.mdpi.com/2072-6694/12/1/185 |
| work_keys_str_mv | AT nicolettacoccaro molecularcomplexityofdiffuselargebcelllymphomacanitbearoadmapforprecisionmedicine AT luisaanelli molecularcomplexityofdiffuselargebcelllymphomacanitbearoadmapforprecisionmedicine AT antonellazagaria molecularcomplexityofdiffuselargebcelllymphomacanitbearoadmapforprecisionmedicine AT tommasinaperrone molecularcomplexityofdiffuselargebcelllymphomacanitbearoadmapforprecisionmedicine AT giorginaspecchia molecularcomplexityofdiffuselargebcelllymphomacanitbearoadmapforprecisionmedicine AT francescoalbano molecularcomplexityofdiffuselargebcelllymphomacanitbearoadmapforprecisionmedicine |